The present invention relates to an organic light emitting diode comprising: a first electrode; a second electrode facing the first electrode; a hole injecting layer or a hole transport layer, which is interposed between the first electrode and the second electrode; and a light emitting layer, wherein the hole injecting layer or the hole transport layer comprises at least one type of amine compound represented by chemical formula A or chemical formula B, and the chemical formula A and the chemical formula B are the same as those included in the description of the invention.

Disclosed are spirocyclic compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and treating cancer, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Disclosed are spirocyclic compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and treating cancer, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I):

##STR00001##

variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.

Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I):

##STR00001##

variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Described herein are compounds represented by formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, Y.sup.1, Y.sup.2, D, E, G.sup.1, G.sup.2, n and p are as defined herein.

##STR00001##

Described herein are compounds represented by formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, Y.sup.1, Y.sup.2, D, E, G.sup.1, G.sup.2, n and p are as defined herein.

##STR00001##

The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.